Blinking and Yawning in Epilepsy: The Role of Dopamine (BYE BYE DOPA)
|First Received Date ICMJE||June 14, 2011|
|Last Updated Date||February 5, 2015|
|Start Date ICMJE||September 2011|
|Primary Completion Date||December 2012 (final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT01432821 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Blinking and Yawning in Epilepsy: The Role of Dopamine|
|Official Title ICMJE||Dopaminergic Reactivity In Idiopathic Generalized Epilepsy: A "Proof Of Concept" Clinical, Pharmacological And Neurophysiological Study|
The objective of the present study is to assess dopaminergic reactivity with behavioural markers (i.e. yawning and blinking) in patients with idiopathic generalized epilepsy compared to matched healthy controls, after injection of either low dose of apomorphine or placebo.
Other parameters will be recorded: biochemical (prolactin, GH) and neurophysiological (Spike-Waves Discharge: SWD rating). Safety parameters will be recorded to assess tolerance.
Clinical data regarding the effects of dopaminergic drugs in idiopathic generalized epilepsies are scarce. The general observation that antipsychotic agents (dopaminergic antagonists) worsen seizures, has suggested that dopaminergic agonists would have antiepileptic effects. However, this has never been clearly demonstrated, besides in few limited studies (Mervaala, 1990 ; Quesney, 1980, 1981). More recently, Positron Emission Tomography (PET) investigations using dopaminergic markers (Fluoro-Dopa, SCH23390, DAT) have shown dopaminergic deficits in several epileptic syndromes: ring chromosome 20 syndrome (Biraben 2004), juvenile myoclonic epilepsy (Ciumas 2008), temporal lobe epilepsy (Bouilleret 2008), frontal lobe epilepsy (Fedi 2008). These data give rise to a renewal of interest for the involvement of the dopaminergic neurotransmission in epilepsies. Based on our experimental data from animal studies (see Deransart and Depaulis, 2002), the investigators propose an original study investigating the involvement of the dopaminergic system in idiopathic generalized epilepsies using behavioural as well as neurophysiological markers of the dopaminergic response, in conditions where seizing activities in patients are facilitated (EEG follow-up after sleep deprivation). This approach is based on the concept developed in our laboratory concerning the involvement of the basal ganglia, and more precisely the dopaminergic pathways, in the control of spike-wave discharges in idiopathic generalized epilepsies.
The primary objective is to assess dopaminergic reactivity using a behavioural marker (i.e. yawning) in patients with idiopathic generalized epilepsy compared to matched healthy controls after injection of either low dose of apomorphine or placebo. Other parameters will be recorded as secondary outcomes: behavioural (blinking), biochemical (prolactin, GH) and neurophysiological (Spike-Waves Discharge: SWD rating) markers. Safety parameters will be recorded to assess tolerance.
Experimental data: hyperdopaminergic response in a model of absence-epilepsy in the rat. Since the late 80's, our laboratory has demonstrated the existence of an endogenous neural mechanism that controls the occurrence of epileptic seizures in different animal models, a system based on the hypothesis that the basal ganglia modulate the synchronisation of epileptic rhythmic activities (Depaulis 1994). The studies performed in GAERS (Genetic Absence Epilepsy Rats from Strasbourg, a validated model of absence-epilepsy in rat) have shown that inhibition of the main output structure of basal ganglia (i.e., the substantia nigra pars reticulata) had antiepileptic effects (Depaulis 1994; Deransart 1996). Similarly, deep brain stimulation of the substantia nigra pars reticulata as well as of the subthalamic nucleus interrupts seizures (Vercueil 1998; Feddersen 2007). Systemic and intrastriatal dopamimetics injections in GAERS also suppress seizures, whereas antagonists worsen them (Warter et al, 1988; Deransart et al., 2000). Electrophysiological data showed respectively decreased and increased activity of DA neurons during and at the end of absence-seizures (Lücking et al. 2002). An increase in D3 receptor transcripts was also observed in adult GAERS as compared to inbred non epileptic control rats (NEC), within the ventral striatum (Deransart et al. 2001). These data suggest changes in the DA tone in GAERS with fully developed epileptic phenotype. According to the key role of DA D3 neurotransmission in the foetal cortical development (Levant B, 1995) and modulation of DA tone (Nissbrandt et al., 1995; Gilbert et al., 1995; Kreiss et al., 1995), the researchers investigated whether the putative impaired DA tone in GAERS correlates with functional changes in spontaneous and quinpirole-induced yawning behaviour (Kurashima et al. 1995; Collins et al.2005). The hypothesis of an increased dopaminergic tone in GAERS was thus addressed using pharmacology and microdialysis. In GAERS and NEC (i) spontaneous and quinpirole-induced yawning behaviour and (ii) changes in intra-accumbens dopamine contents induced by amphetamine and K+ and measured by microdialysis were investigated. Spontaneous yawning was significantly decreased in GAERS (0.3±0.2 yawn/hr, n=9) as compared to NEC (5.4±1.2, n=8) and Wistar Harlan rats (9.7±2.3, n=7). Quinpirole-induced yawning was significantly increased in GAERS (29.4±4.9) as compared to NEC (10.5±2.7) and Wistar-Harlan rats (22.6±3.5). Quinpirole also increased the number of absence-seizures in GAERS (+47.4±8.6%). When compared to NEC, basal levels of DA were 40% lower in GAERS whereas amphetamine and K+ produced a higher increase in extracellular dopamine in GAERS. The increased quinpirole-induced yawning in GAERS may account for an overexpression in D3 transcripts. The increased responsiveness of dopamine transmission observed in GAERS after pharmacological manipulations, as compared to NEC, suggests a " hyperdopaminergic " phenotype of GAERS. Altogether, these data support that GAERS have an impaired DA tone that may be associated with the development of mechanisms controlling absences seizures (Deransart et al, in preparation).
Altogether, these data suggest that a phasic involvement (" on request ") of the basal ganglia - notably under the influence of the dopaminergic neurotransmission - may underlie the rapid changes in extracellular activity recorded in output structures of the basal ganglia at the end of seizures in this model (Deransart 2003). Such a phasic functioning of the dopaminergic system in the control of seizures could also reconcile with the apparent discrepancy regarding the fact that seizures appear to escape chronic high-frequency stimulations of the substantia nigra (Feddersen 2007). These data strengthen the need for a re-appraisal of clinical approaches, especially based from a dynamic point of view regarding the involvement of the dopaminergic system in epilepsy.
This project arises from concepts developed in our laboratory from experimental data obtained in an animal model of epilepsy and from recent clinical data from the literature. It aims at improving understanding of dopaminergic transmission dynamics in patients with epilepsy. It could therefore promote the emergence of new markers of susceptibility to epileptic seizures and constitute an opportunity to develop new pharmacological approaches based on dopaminergic neuromodulation.
|Study Type ICMJE||Interventional|
|Study Phase||Not Provided|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
|Condition ICMJE||Idiopathic Generalized Epilepsy|
|Intervention ICMJE||Other: Apomorphine (Experimental product)
Dosage Form: Injection Dosage: 1 or 5 mg / kg
Route of administration: Subcutaneous
Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.
Two injections will be made by visiting during visits 2 and 3.
The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:
|Study Arm (s)||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Active, not recruiting|
|Estimated Enrollment ICMJE||50|
|Estimated Completion Date||September 2015|
|Primary Completion Date||December 2012 (final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
For healthy volunteers:
Criteria for non-inclusion
|Ages||18 Years to 40 Years|
|Accepts Healthy Volunteers||Yes|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||France|
|Removed Location Countries|
|NCT Number ICMJE||NCT01432821|
|Other Study ID Numbers ICMJE||C10-27|
|Has Data Monitoring Committee||No|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Institut National de la Santé Et de la Recherche Médicale, France|
|Study Sponsor ICMJE||Institut National de la Santé Et de la Recherche Médicale, France|
|Collaborators ICMJE||Not Provided|
|Information Provided By||Institut National de la Santé Et de la Recherche Médicale, France|
|Verification Date||February 2015|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP